Episode 156: J&J's vaccine pause, talking about remote risks, & why no new drugs for Covid-19
How do you describe a one-in-a-million risk? What's heparin-induced thrombocytopenia? And why's it so hard to find drugs for Covid-19?\n\nWe cover all that and more this week on \u201cThe Readout LOUD,\u201d STAT\u2019s biotech podcast. First, Science Magazine reporter Kai Kupferschmidt joins us to discuss the U.S. decision to press pause on the Johnson & Johnson vaccine and what researchers have learned about rare cases of dangerous clotting. Then, biotech analyst Josh Schimmer joins us to talk about why the drug industry has had such a hard time coming up with treatments for Covid-19 and offer some tips that might help in the next pandemic.